Simple Summary Glioblastoma is the most common and aggressive malignant primary brain
cancer in adults. The prognosis remains poor following standard-of-care treatment with …

Cilengitide, a cyclic RGD pentapeptide, is currently in clinical phase III for treatment of
glioblastomas and in phase II for several other tumors. This drug is the first anti-angiogenic …

Inhibitors of αvβ3 and αvβ5 integrin have entered clinical trials as antiangiogenic agents for
cancer treatment but generally have been unsuccessful. Here we present in vivo evidence …

It is now recognized that the host microenvironment undergoes extensive change during the
evolution and progression of cancer. This involves the generation of cancer‐associated …

Syndecan-1 (Sdc1) is a matrix receptor shown to associate via its extracellular domain with
the αvβ3 and αvβ5 integrins, potentially regulating cell adhesion, spreading, and invasion of …

Targeting drugs to receptors involved in tumor angiogenesis is a novel and promising
approach to improve cancer treatment. In this study, we evaluated the antitumor activity of …

Cancer is not only composed malignant epithelial component but also stromal components
such as fibroblasts, endothelial cells, and inflammatory cells, by which an appropriate tumor …

Brain tumors are highly angiogenesis dependent. The cell adhesion receptor integrin αvβ3
is overexpressed in glioma and activated endothelial cells and plays an important role in …

Cell adhesion molecules αvβ3 and αvβ5 play a pivotal role in tumor angiogenesis and
metastasis. Antiangiogenic therapy by using small peptide antagonists of αv-integrins slows …

Vascularization of bone defects is considered a crucial component to the successful
regeneration of large bone defects. Although vascular endothelial growth factor (VEGF) has …